纳米酶介导的谷胱甘肽耗竭用于增强基于活性氧的癌症治疗：综述
Nanozyme-mediated glutathione depletion for enhanced ROS-based cancer therapies: a comprehensive review.
作者信息
Wang Xinyu, Wei Nan, Zhang Yang, Fang Yuan, Li Yijun, Li Songguo, Wang Zhanggui, Sun Chenglong
机构信息
School of Medicine, Anhui University of Science and Technology, Huainan, Anhui, People's Republic of China.
Department of radiotherapy, Anhui No.2 Provincial People's Hospital, Hefei, Anhui, people's Republic of China.
出版信息
Nanomedicine (Lond). 2025 Feb;20(3):279-290. doi: 10.1080/17435889.2024.2446138. Epub 2024 Dec 27.
Nanozymes can improve reactive oxygen species (ROS)-based cancer therapies by targeting cancer cells' antioxidant defense mechanisms, particularly glutathione (GSH) depletion, to overcome ROS-resistant cancer cells. Nanozymes, innovative enzyme-mimetic nanomaterials, can generate ROS, alter the tumor microenvironment (TME), and synergize with photodynamic therapy (PDT), chemodynamic therapy (CDT), radiotherapy, and immunotherapy. This review shows how nanozymes catalyze ROS generation, selectively deplete GSH, and target cancer elimination, offering clear advantages over standard therapies. Nanozymes selectively target cancer cells' antioxidant defenses to improve PDT, CDT, and radiation therapies. To maximize nanozyme-based cancer treatment efficacy, biodistribution, biocompatibility, and tumor heterogeneity must be assessed. To improve cancer treatment, multifunctional, stimuli-responsive nanozymes and synergistic combination drugs should be developed.
纳米酶可以通过靶向癌细胞的抗氧化防御机制，特别是谷胱甘肽（GSH）耗竭，来改善基于活性氧（ROS）的癌症治疗，从而克服对ROS具有抗性的癌细胞。纳米酶是创新的模拟酶纳米材料，可产生活性氧，改变肿瘤微环境（TME），并与光动力疗法（PDT）、化学动力疗法（CDT）、放射疗法和免疫疗法协同作用。这篇综述展示了纳米酶如何催化活性氧的产生、选择性地消耗谷胱甘肽以及靶向消除癌症，与标准疗法相比具有明显优势。纳米酶选择性地靶向癌细胞的抗氧化防御，以改善光动力疗法、化学动力疗法和放射疗法。为了最大化基于纳米酶的癌症治疗效果，必须评估其生物分布、生物相容性和肿瘤异质性。为了改善癌症治疗，应开发多功能、刺激响应性纳米酶和协同组合药物。
Zotero 插件